Last year the FTC negotiated a consent order with Google Inc. and its subsidiary Motorola Mobility (MMI) resolving charges that the companies engaged in unfair competition by violating the FRAND commitments for some of MMI’s standard-essential patents (SEPs). A key feature in the Commission’s Order is a requirement that Google offer potential licensees binding arbitration when negotiations over licensing SEPs break down.
When was your last health exam? Just as we (are supposed to) get regular check-ups from our health care providers, the FTC thinks it is smart to do a periodic check-up on the health care industry itself. Health care is a critical sector of the U.S. economy, affecting the lives of all American consumers.
Every year, we receive thousands of emails, letters, and phone calls from businesses and consumers relating facts they believe present an antitrust concern. The Bureau welcomes inquiries from the public because a call or email can be the source of information that leads to an antitrust enforcement action to stop or prevent anticompetitive conduct. More generally, an important part of the FTC’s mission is to promote public understanding of the competitive process. So, in addition to our law enforcement duties, it’s our job to listen and to educate.
As Yogi Berra reputedly said, “It’s tough to make predictions, especially about the future.” But that is precisely the job Congress gave to antitrust enforcers nearly 100 years ago when it passed the Clayton Act and established the Federal Trade Commission, in part, to enforce it. By its terms, the Clayton Act was designed to deal with antitrust violations before they occur, to address them in their incipiency.
A few minutes ago, FTC Chairwoman Edith Ramirez delivered opening remarks to kick off today’s FTC workshop exploring emerging issues affecting competition and patient access to biologic medicines.
You can view a live webcast of the workshop on the FTC’s website, or follow live tweets all day at #FTCFOB.
Tomorrow, the FTC will host a workshop to explore emerging issues affecting competition and consumer access to biologic medicines.